Allworth Financial LP - LINEAGE CELL THERAPEUTICS IN ownership

LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 115 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q2 2021. The put-call ratio across all filers is 0.65 and the average weighting 0.1%.

Quarter-by-quarter ownership
Allworth Financial LP ownership history of LINEAGE CELL THERAPEUTICS IN
ValueSharesWeighting
Q3 2023$5,605
-16.3%
4,7500.0%0.00%
Q2 2023$6,698
-6.0%
4,7500.0%0.00%
Q1 2023$7,125
+28.2%
4,7500.0%0.00%
Q4 2022$5,558
+11.2%
4,7500.0%0.00%
Q3 2022$5,000
-37.5%
4,7500.0%0.00%
Q2 2022$8,000
+14.3%
4,7500.0%0.00%
Q1 2022$7,000
-41.7%
4,7500.0%0.00%
Q4 2021$12,0000.0%4,7500.0%0.00%
Q3 2021$12,000
-14.3%
4,7500.0%0.00%
Q2 2021$14,0004,7500.00%
Other shareholders
LINEAGE CELL THERAPEUTICS IN shareholders Q2 2021
NameSharesValueWeighting ↓
BROADWOOD CAPITAL INC 34,935,485$39,477,0003.01%
Raffles Associates 2,080,536$2,351,0002.51%
Defender Capital, LLC. 5,184,035$5,862,0002.30%
Prescott General Partners LLC 1,851,851$2,093,0000.16%
DAFNA Capital Management LLC 140,000$158,0000.04%
Fort Sheridan Advisors LLC 83,931$95,0000.03%
Long Focus Capital Management, LLC 215,000$243,0000.02%
XTX Topco Ltd 72,807$82,0000.02%
Ergoteles LLC 490,895$555,0000.02%
Beirne Wealth Consulting Services, LLC 45,000$51,0000.02%
View complete list of LINEAGE CELL THERAPEUTICS IN shareholders